BamSEC and AlphaSense Join Forces
Learn More

Ligand Pharmaceuticals Incorporated

NASDAQ: LGND    
Share price (12/20/24): $114.64    
Market cap (12/20/24): $2.166 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 8 pages Severance Agreement and General Release
12/34/56
EX-10.2
from 10-Q 88 pages Purchase and Sale Agreement Dated as of May 6, 2024 by and Among Agenus Inc., Agenus Royalty Fund, LLC, Agenus Holdings 2024, LLC and Ligand Pharmaceuticals Incorporated
12/34/56
EX-10.2
from S-8 2 pages Amendment to the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan
12/34/56
EX-10.45
from 10-K 17 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because Ligand Pharmaceuticals Incorporated Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to Ligand Pharmaceuticals Incorporated if Publicly Disclosed
12/34/56
EX-10.44
from 10-K 3 pages First Amendment to Development Funding and Royalties Agreement
12/34/56
EX-10.12
from 10-K 1 page Amendment to Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan
12/34/56
EX-10.1
from 10-Q 3 pages Ligand Pharmaceuticals Incorporated Director Compensation and Stock Ownership Policy (Amended and Restated Effective August 4, 2023) I. Director Compensation
12/34/56
EX-10.3
from 10-Q 16 pages Change in Control Severance Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Ligand Pharmaceuticals Incorporated Director Compensation and Stock Ownership Policy (Amended and Restated Effective April 19, 2023) I. Director Compensation
12/34/56
EX-10.15
from 10-K 11 pages Severance Agreement
12/34/56
EX-10.14
from 10-K 14 pages Separation Agreement
12/34/56
EX-10.9
from 10-K 3 pages Ligand Pharmaceuticals Incorporated Director Compensation and Stock Ownership Policy (Amended and Restated Effective April 13, 2020) I. Director Compensation
12/34/56
EX-10.8
from 10-K 28 pages Ligand Pharmaceuticals Incorporated Amended and Restated Severance Plan and Summary Plan Description Effective Date: November 1, 2022
12/34/56
EX-10.1
from 10-Q 26 pages Amended and Restated Employee Matters Agreement
12/34/56
EX-10.1
from 8-K 31 pages Tax Matters Agreement by and Among Omniab, Inc. (F/K/a Avista Public Acquisition Corp. II) Ligand Pharmaceuticals Incorporated and Omniab Operations, Inc. (F/K/a Omniab, Inc.) Dated as of November 1, 2022 Table of Content I II Tax Matters Agreement
12/34/56
EX-10.5
from 10-Q 7 pages Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement
12/34/56
EX-10.4
from 10-Q 6 pages Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement
12/34/56
EX-10.3
from 10-Q 8 pages Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan Notice of Grant of Stock Option
12/34/56
EX-10.2
from 10-Q 18 pages Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan Article 1 General Provisions
12/34/56
EX-10.2
from S-8 7 pages Ligand Pharmaceuticals Incorporated Notice of Grant of Non-Qualified Inducement Stock Option
12/34/56